Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The JenaValve ALIGN-AR Pivotal Trial
NCT04415047 · View on ClinicalTrials.gov ↗
Study Summary
To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.
Conditions Studied
Interventions
- DEVICE JenaValve Trilogy Heart Valve System
Study Locations (20)
California
- Cedars Sinai Medical Center — Los Angeles
- Scripps Hospital — San Diego
- California Pacific Medical Center Research Institute — San Francisco
Ohio
- The Christ Hospital — Cincinnati
- Cleveland Clinic Foundation — Cleveland
- Ohio Health Research Institute — Columbus
Georgia
- Piedmont Healthcare — Atlanta
- Emory University Hospital — Atlanta
Michigan
- University of Michigan — Ann Arbor
- Henry Ford Health System — Detroit
Arizona
- TMC HealthCare & PIMA Heart — Tucson
District of Columbia
- MedStar Washington Hospital Center — Washington D.C.
Florida
- Morton Plant/ BayCare Health — Clearwater
Illinois
- Cardiac Surgery Clinical Research Center Inc./ Advocate Aurora Health — Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2028-08 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415047
The ClinicalTrials.gov registry entry for NCT04415047 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JenaValve Technology, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Aortic Valve Disease appearing as the primary indexed condition, and to 1 intervention — of which JenaValve Trilogy Heart Valve System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04415047 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Ohio, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04415047 about?
NCT04415047 is a clinical study titled "The JenaValve ALIGN-AR Pivotal Trial". To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aort...
What is the current status of trial NCT04415047?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2020-05-22. Estimated completion is 2028-08.
What conditions does trial NCT04415047 study?
This clinical trial studies the following conditions: Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation, Aortic Insufficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04415047?
The interventions under investigation include: JenaValve Trilogy Heart Valve System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04415047?
This trial is sponsored by JenaValve Technology, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04415047 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.